Maarten Cozijnsen

131 Chapter 6 Benefits and risks of combination therapy in children with IBD Endpoints Results** a) Non melanoma skin cancer b) Other malignancies a) 11/1401=0.8/100PY vs. [2] 4/1649=0.2/100PY, RR: 2.82 (1.07-7.44) b) 14/1401=1.0/100PY vs. [2] 6/1649=0.4/100PY, RR: 3.46 (1.08-11.06) a) Malignancy rates b) Malignancy risk (HR) a) [1] 119/3,517 (3.4%), OR 3.33 (0.46-24) vs. [2] 5/247 (2.0%), OR 1.96 (0.23-17) vs [3] 102/2,413 (4.2), OR4.19 (0.58-30) b) [1] 1.22 (0.81-1.86), P=0.34 and [2] 0.59 (0.28-1.22), P=0.16 and [3] 1.43 (0.92-2.21), P=0.11 Lymphoma risk [1] 1/678PY, SIRR 6.6 (4.4-8.8) [2] 1/774PY, SIRR 5.2 (3.5-6.8) [3] 4/8723PY, SIRR 1.4 (1.2-1.7) a) Non hodgkin lymphoma/other events b) Hepato-splenic T-cell lymphoma/other events a) [1] 36/12 vs. [2] 6/71 vs. [3] 1/14 vs. [4] 1/14; [1] vs. [4] OR=4.98–354.09 , [2] vs. [4] OR=0.13–10.61, [3] vs. [4] OR=8.32-945.38 b) [1] 23/12 vs. [2] 1/71 vs. [3] 17/3 vs. [4] 0/14, [1] vs. [4] OR=2.99–993.04 , [2] vs. [4] OR=0.02–15.70, [3] vs. [4] OR=6.90-3045.2